Future of cord blood for non-oncology uses

G. Kögler, P. Critser, T. Trapp, Mervin Yoder

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

For the last 5 years cord blood (CB) has been under intense experimental investigation in in vitro differentiation models and in preclinical animal models ranging from bone to muscle regeneration, cardiovascular diseases including myocardial and peripheral arterial disease, stroke and Parkinson's disease. On the basis of its biological advantages, CB can be an ideal source for tissue regeneration. However, in the hype of the so-called plasticity, many cell types have been characterized either on cell surface Ag expression alone or by RNA expression only, and without detailed characterization of genetic pathways; frequently, cells are defined without analysis of cellular function in vitro and in vivo, and the definition of the lineage of origin and cells have not been defined in preclinical studies. Here, we explore not only the most consistent data with regard to differentiation of CB cells in vitro and in vivo, but also show technical limitations, such as why in contrast to cell populations isolated from fresh CB, cryopreserved CB is not the ideal source for tissue regeneration. By taking advantage of numerous CB units discarded due to lack of sufficient hematopoietic cells for clinical transplantation, new concepts to produce off-the-shelf products are presented as well.

Original languageEnglish
Pages (from-to)683-697
Number of pages15
JournalBone Marrow Transplantation
Volume44
Issue number10
DOIs
StatePublished - Nov 2009

Fingerprint

Fetal Blood
Regeneration
Peripheral Arterial Disease
Cell Transplantation
Parkinson Disease
Blood Cells
Cardiovascular Diseases
Animal Models
Stroke
RNA
Bone and Bones
Muscles
Population
In Vitro Techniques

Keywords

  • Differentiation of CB cells
  • Regenerative therapeutics
  • Stem cells
  • Tissue regeneration

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Future of cord blood for non-oncology uses. / Kögler, G.; Critser, P.; Trapp, T.; Yoder, Mervin.

In: Bone Marrow Transplantation, Vol. 44, No. 10, 11.2009, p. 683-697.

Research output: Contribution to journalArticle

Kögler, G. ; Critser, P. ; Trapp, T. ; Yoder, Mervin. / Future of cord blood for non-oncology uses. In: Bone Marrow Transplantation. 2009 ; Vol. 44, No. 10. pp. 683-697.
@article{9dfac549e308446a9e9d701fbc369372,
title = "Future of cord blood for non-oncology uses",
abstract = "For the last 5 years cord blood (CB) has been under intense experimental investigation in in vitro differentiation models and in preclinical animal models ranging from bone to muscle regeneration, cardiovascular diseases including myocardial and peripheral arterial disease, stroke and Parkinson's disease. On the basis of its biological advantages, CB can be an ideal source for tissue regeneration. However, in the hype of the so-called plasticity, many cell types have been characterized either on cell surface Ag expression alone or by RNA expression only, and without detailed characterization of genetic pathways; frequently, cells are defined without analysis of cellular function in vitro and in vivo, and the definition of the lineage of origin and cells have not been defined in preclinical studies. Here, we explore not only the most consistent data with regard to differentiation of CB cells in vitro and in vivo, but also show technical limitations, such as why in contrast to cell populations isolated from fresh CB, cryopreserved CB is not the ideal source for tissue regeneration. By taking advantage of numerous CB units discarded due to lack of sufficient hematopoietic cells for clinical transplantation, new concepts to produce off-the-shelf products are presented as well.",
keywords = "Differentiation of CB cells, Regenerative therapeutics, Stem cells, Tissue regeneration",
author = "G. K{\"o}gler and P. Critser and T. Trapp and Mervin Yoder",
year = "2009",
month = "11",
doi = "10.1038/bmt.2009.287",
language = "English",
volume = "44",
pages = "683--697",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Future of cord blood for non-oncology uses

AU - Kögler, G.

AU - Critser, P.

AU - Trapp, T.

AU - Yoder, Mervin

PY - 2009/11

Y1 - 2009/11

N2 - For the last 5 years cord blood (CB) has been under intense experimental investigation in in vitro differentiation models and in preclinical animal models ranging from bone to muscle regeneration, cardiovascular diseases including myocardial and peripheral arterial disease, stroke and Parkinson's disease. On the basis of its biological advantages, CB can be an ideal source for tissue regeneration. However, in the hype of the so-called plasticity, many cell types have been characterized either on cell surface Ag expression alone or by RNA expression only, and without detailed characterization of genetic pathways; frequently, cells are defined without analysis of cellular function in vitro and in vivo, and the definition of the lineage of origin and cells have not been defined in preclinical studies. Here, we explore not only the most consistent data with regard to differentiation of CB cells in vitro and in vivo, but also show technical limitations, such as why in contrast to cell populations isolated from fresh CB, cryopreserved CB is not the ideal source for tissue regeneration. By taking advantage of numerous CB units discarded due to lack of sufficient hematopoietic cells for clinical transplantation, new concepts to produce off-the-shelf products are presented as well.

AB - For the last 5 years cord blood (CB) has been under intense experimental investigation in in vitro differentiation models and in preclinical animal models ranging from bone to muscle regeneration, cardiovascular diseases including myocardial and peripheral arterial disease, stroke and Parkinson's disease. On the basis of its biological advantages, CB can be an ideal source for tissue regeneration. However, in the hype of the so-called plasticity, many cell types have been characterized either on cell surface Ag expression alone or by RNA expression only, and without detailed characterization of genetic pathways; frequently, cells are defined without analysis of cellular function in vitro and in vivo, and the definition of the lineage of origin and cells have not been defined in preclinical studies. Here, we explore not only the most consistent data with regard to differentiation of CB cells in vitro and in vivo, but also show technical limitations, such as why in contrast to cell populations isolated from fresh CB, cryopreserved CB is not the ideal source for tissue regeneration. By taking advantage of numerous CB units discarded due to lack of sufficient hematopoietic cells for clinical transplantation, new concepts to produce off-the-shelf products are presented as well.

KW - Differentiation of CB cells

KW - Regenerative therapeutics

KW - Stem cells

KW - Tissue regeneration

UR - http://www.scopus.com/inward/record.url?scp=75149125985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149125985&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.287

DO - 10.1038/bmt.2009.287

M3 - Article

C2 - 19802027

AN - SCOPUS:75149125985

VL - 44

SP - 683

EP - 697

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -